Arrowhead Pharmaceuticals (ARWR)
(Real Time Quote from BATS)
$21.78 USD
-0.83 (-3.67%)
Updated Apr 19, 2024 03:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ARWR 21.78 -0.83(-3.67%)
Will ARWR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARWR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARWR
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
ARWR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARWR
First Week of December 20th Options Trading For Arrowhead Pharmaceuticals (ARWR)
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Wolfe upgrades Ionis to outperform, cites upcoming catalysts
Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results
Madrigal announces US launch of NASH/MASH drug Rezdiffra